Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02645357
Other study ID # IRST100.23
Secondary ID
Status Completed
Phase N/A
First received December 31, 2015
Last updated February 8, 2017
Start date November 2015
Est. completion date January 2017

Study information

Verified date February 2017
Source Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Implementing an evidence-based computerized decision support system linked to electronic health records to improve care for cancer patients.

The ONCO-CODES (Computerized DEcision Support in ONCOlogy) trial is a pragmatic, parallel group, randomized controlled study with 1:1 allocation ratio Study Duration 12 month Study Center(s) Single-center

Objectives:

The primary outcome of this trial is a process outcome. i.e. the rate at which the issues reported by the reminders are resolved (resolution rates).


Description:

Implementing an evidence-based computerized decision support system linked to electronic health records to improve care for cancer patients.

Short Title/Acronym ONCO-CODES Protocol Code IRST100.23

Rationale:

Computerized decision support systems (CDSSs) are computer programs that provide clinicians, staff, patients, or other individuals with person-specific, actionable recommendations or management options that are intelligently filtered or presented at appropriate times to enhance health and health care. CDSSs might be integrated with patient electronic health records (EHRs) and evidence-based knowledge. The Investigators designed a pragmatic randomized controlled trial to evaluate the effectiveness of patient-specific, point-of-care reminders generated by the Medilogy Decision Support System (MediDSS) on clinical practice and the quality of care in the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. The Investigators hypothesize that MediDSS reminders can increase clinician adherence to guidelines and, eventually, improve the quality of care offered to hospitalized patient. The adoption of CDSSs is likely to increase across healthcare systems due to growing concerns about the quality of medical care and discrepancy between real and ideal practice, continuous calls for a meaningful use of health information technology, and the increasing use of and familiarity with advanced technology among new generations of physicians.

Study Design:

The ONCO-CODES (Computerized DEcision Support in ONCOlogy) trial is a pragmatic, parallel group, randomized controlled study with 1:1 allocation ratio Study Duration 12 month Study Center(s) Single-center

Objectives:

The primary outcome of this trial is a process outcome. i.e. the rate at which the issues reported by the reminders are resolved (resolution rates).

Number of Subjects:

The investigators calculated the sample size on the basis of the primary outcome. A sample of 1,704 reminders will be necessary to detect the difference between the two groups (power = 0.90; α =0.05, two-sided; 1:1 allocation). Since estimates for intracluster correlation are not available, Implementing an evidence-based computerized decision support system linked to electronic health records to improve care for cancer patients.

Diagnosis and Main Inclusion Criteria:

The investigators will include all the patients admitted to the facilities of the IRST IRCCS. There are no exclusion criteria

Statistical Methodology:

All analyses will follow the intention-to-treat principle: patients will be analyzed in the group to which they have been randomized. Descriptive statistics will be presented.

All statistical tests will be two-sided. The investigators will use the Stata software to perform all statistical analyses (Stata Corp., College Station, TX, USA).The investigators increased the required sample size (by 20%) to 2,046 reminders to account for clustering by patient.


Recruitment information / eligibility

Status Completed
Enrollment 15431
Est. completion date January 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- The Investigators will include all the EHRs of patients admitted to the facilities of the IRST IRCCS.

Exclusion Criteria:

- There are no exclusion criteria.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
computer reminders on clinical practice
on-screen, point-of-care computer reminders on clinical practice.
Control group
control group

Locations

Country Name City State
Italy Oncologia Medica, IRST IRCCS, Meldola Meldola

Sponsors (8)

Lead Sponsor Collaborator
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Catholic University of the Sacred Heart, Duodecim, Finnish Medical Association, Helsinki, Istituto Ortopedico Galeazzi, Mario Negri Institute for Pharmacological Research, Ministry of Health, Italy, Ottawa Hospital Research Institute, University of Milan

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary resolution rates the rate at which the issues reported by the reminders are resolved 12 months
See also
  Status Clinical Trial Phase
Completed NCT02824042 - Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Phase 1
Completed NCT02253420 - COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients Phase 1
Completed NCT02357953 - Transpulmonary Thermodilution Using an Implented Central Venous Access Port N/A
Recruiting NCT04931329 - Onco-haematology Vigilance Card
Terminated NCT02138812 - Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel Phase 1
Recruiting NCT05356182 - A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies N/A
Terminated NCT02368951 - Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) Phase 1
Not yet recruiting NCT05423808 - Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients. N/A
Terminated NCT02439346 - Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel Phase 1
Recruiting NCT05385718 - Ezra Faster Scan Study
Completed NCT02457351 - Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study Phase 1
Completed NCT02906423 - Results From a Health System-wide Implementation of a Quality of Life Questionnaire N/A
Completed NCT01409135 - A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4 Phase 1
Not yet recruiting NCT02327806 - The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance N/A
Completed NCT02639091 - Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Phase 1
Completed NCT02366949 - Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel Phase 1
Not yet recruiting NCT06097533 - Improvement of Quality of Life by Cannabinoids in Oncologic Patients Phase 2/Phase 3
Completed NCT02427490 - A Problem-Solving Intervention for Family Caregivers in Palliative Oncology N/A
Recruiting NCT05359848 - A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy N/A